New preclinical study data now accessible via the Critical Path Institute
Data from the PAN-TB Collaboration’s 4 nonclinical studies—covering combination pharmacokinetics, relapsing mouse model (RMM) efficacy, and CFU-R/S ratio mouse model (CRSMM) efficacy—are now available through the Critical Path Institute Data Analytics Platform (CP-DAP).
These studies evaluated the pharmacokinetics and efficacy of novel three– and four-drug combinations of the following priority anti-TB drugs and drug candidates: Bedaquiline (B), Sorfequiline (formerly TBAJ-876), Pretomanid (Pa), Sutezolid (Sut), GSK2556286 (286), GSK3036656 (656), TBD09 (formerly MK-7762), TBD11 (formerly mCLB073), Quabodepistat (Q) (formerly OPC167832 or OPC), Rifapentine (P), Isoniazid (H), Pyrazinamide (P) and Moxifloxacin (M).
Study data available:
- Pharmacokinetic assessments of novel four-drug combinations in mice to inform RMM and CRSMM efficacy studies.
- RMM evaluations of 12 novel three and four anti-TB drug combinations, assessing bactericidal and sterilizing activity over time, drug pharmacokinetics, and the RS ratio as a pharmacodynamic marker.
- CRSMM evaluations of five prioritized four-drug regimens from Wave 2022 and Wave 2023 and corresponding three-drug backbones, where B is replaced by Sorfequiline (formerly TBAJ-876), assessing bactericidal activity, RS ratio trends, and individual drug contributions.
All available data are mapped to the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data (SEND). Please note that C-Path has migrated to a new, enhanced platform, which will provide expanded functionality and capabilities for researchers. All available PAN-TB Collaboration data, including earlier 2020-2023 nonclinical studies, are available through the new platform.
Researchers can request access to the data by following the link below. New data will be added as they become available.
